Table S1.
Drug acquisition costs
| Product | Dosage | Price per package (including all taxes) (EUR) | Dispensing fee (EUR) | Monthly treatment cost (EUR) |
|---|---|---|---|---|
| Compared treatments | ||||
| Afatinib (GIOTRIF®; Boehringer Ingelheim, Ingelheim, Germany) 40 mg; 28 tablets CIP: 3400927565878 |
40 mg/day orally | 1,870.48 | 1.02/pack | 2,033.04 |
| Erlotinib (TARCEVA®; Roche, Basel, Switzerland) 150 mg; 30 tablets CIP: 3400936923522 |
150 mg/day orally | 2,071.92 | 1.02/pack | 2.072.94 |
| Post-progression treatments for additional sensitivity analyses | ||||
| Nivolumab (OPDIVO®; Bristo-Myers Squibb, New York, NY, USA) 10 mg/mL; vial of 10 mL* |
3 mg/kg every 2 weeks intravenously until death | 1,344.33 | N/A | 8,757.66 |
| Docetaxel | 75 mg/m2 every 3 weeks intravenously | Cost included in DRG cost | Cost included in DRG cost | Cost included in DRG cost |
| Paclitaxel | 200 mg/m2 every 3 weeks intravenously | Cost included in DRG cost | Cost included in DRG cost | Cost included in DRG cost |
| Best supportive care | N/A | N/A | N/A | N/A |
Note:
*
UK cost estimated in euros using an exchange rate of 1.19474 (July 2016).
Abbreviations: CIP, Club Inter Pharmaceutique (ID code for pharmaceuticals in France); DRG, diagnosis-related group; N/A, not applicable.